Company news

Glaukos Corporation news in 2026

Glaukos Corporation's news releases, calls and decks from 2026, newest first.

View company

Glaukos Announces Participation in Upcoming Investor Conferences

November 3, 2026

Third Quarter 2026 GAAP to Non-GAAP Recs

October 28, 2026

Glaukos Announces Third Quarter 2026 Financial Results

October 28, 2026

Glaukos Announces Positive Topline Results from Phase 4 Prospective Randomized Controlled Clinical Trial Evaluating iDose® TR in Combination with Cataract Surgery

October 9, 2026

Glaukos Announces Exclusive License Agreement with RevOpsis Therapeutics to Develop and Commercialize RO-104, a First-in-Class Tri-Specific Biologic for Retinal Diseases

October 8, 2026

Glaukos Announces Positive Three-Year Epioxa® Results Demonstrating Durable Clinical Outcomes in Keratoconus

October 7, 2026

Glaukos Announces Second Quarter 2026 Financial Results

July 29, 2026

Glaukos Announces Completion of Patient Enrollment in 510(k) Pivotal Study for PRESERFLO™ MicroShunt

July 27, 2026

Glaukos to Release Second Quarter 2026 Financial Results after Market Close on July 29

July 8, 2026

Glaukos Announces Completion of Patient Enrollment in Phase 2 Study of GLK-321 for Demodex Blepharitis

June 25, 2026

Glaukos Announces First Quarter 2026 Financial Results

April 29, 2026

Glaukos Announces the Release of its 2025 Sustainability Report

April 16, 2026

Glaukos Receives Permanent J-code for Epioxa™

April 15, 2026

Glaukos to Release First Quarter 2026 Financial Results after Market Close on April 29

April 8, 2026

Glaukos to Present Multiple Scientific Abstracts at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

April 6, 2026

Glaukos Announces Commercial Availability of Epioxa, a Transformative Innovation in Interventional Keratoconus Care

March 20, 2026

Glaukos Announces Commercial Availability of Epioxa™, a Transformative Innovation in Interventional Keratoconus Care

March 19, 2026

Annual Report for Fiscal Year Ending December 31, 2025 (Form 10-K)

February 23, 2026

Glaukos Announces Fourth Quarter and Full Year 2025 Financial Results

February 17, 2026

Glaukos Announces US FDA Approval of NDA Supplement Allowing for Re-Administration of iDose TR

January 29, 2026

Glaukos Announces US FDA Approval of NDA Supplement Allowing for Re-Administration of iDose® TR

January 28, 2026

Glaukos to Release Fourth Quarter and Full Year 2025 Financial Results after Market Close on February 17

January 20, 2026

Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Sales and Reaffirms 2026 Revenue Guidance

January 13, 2026

Calls in 2026

Decks in 2026